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Abstract
Liquid perfluorocarbon droplets have been of interest in the medical acoustics community for use
as acoustically activated particles for tissue occlusion, imaging, and therapeutics. To date,
methods to produce liquid perfluorocarbon droplets typically result in a polydisperse size
distribution. Since the threshold of acoustic activation is a function of diameter, there would be
benefit from a monodisperse population to preserve uniformity in acoustic activation parameters.
Through the use of a microfluidic device with flow focusing technology, the production of
droplets of perfluoropentane with a uniform size distribution is demonstrated. Stability studies
indicate that these droplets are stable in storage for at least two weeks. Acoustic studies illustrate
the thresholds of vaporization as a function of droplet diameter, and a logarithmic relationship is
observed between acoustic pressure and vaporization threshold within the size ranges studied.
Droplets of uniform size have very little variability in acoustic vaporization threshold. Results
indicate that microfluidic technology can enable greater manufacturing control of phase change
perfluorocarbons for acoustic droplet vaporization applications.
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Introduction
Acoustic Droplet Vaporization Agents
In acoustic droplet vaporization (ADV), acoustic pressure delivered to a liquid droplet by an
ultrasound (US) transducer provides the additional energy necessary to induce a liquid-to-
gas phase transition. This phase transition allows for unique applications that are not
possible with standard microbubble contrast agents, since ADV agents exhibit a very large
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volume change after activation. Additionally, ADV agents are typically poorly echogenic in
their liquid form, but highly echogenic as gas bubbles.
The basic construction of an ADV agent consists of a volatile liquid core that can be
converted to a gas with additional energy. Typically, ADV droplets consist of
perfluorocarbons (PFC) such as perfluoropentane (PFP)(Zhang et al. 2010), perfluorohexane
(PFH)(Giesecke and Hynynen 2003, Fabiilli et al. 2010), or perfluorooctane (Fabiilli et al.
2009). The most commonly employed perfluorocarbons, PFP and PFH, have boiling points
near physiological temperatures (29 °C and 56 °C, respectively). Recently, stabilization and
ADV capability of droplets of liquid perfluorobutane (boiling point of -1.7 °C) has been
demonstrated (Sheeran et al. 2011).
Producing droplets in the micron and sub-micron range increases the Laplace pressure
exerted on the liquid core, enabling small droplets to be maintained in liquid form even
above their vaporization temperature. The addition of a stabilizing shell reduces droplet
coalescence and increases stability of the emulsions. (Kripfgans et al. 2005, Rapoport et al.
2009a, Sheeran et al. 2011) Commonly utilized methods of producing PFC droplets include
sonication or high-speed mechanical agitation of the host solution, which typically results in
a polydisperse population (Fabiilli et al. 2010, Rapoport et al. 2010).
Acoustic Droplet Vaporization Applications
Liquid perfluorocarbon droplets have been shown to provide ultrasound image contrast
(Kripfgans et al. 2002, Marsh et al. 2007), although the backscatter is notably less than
similarly sized microbubble agents. One of the first commercial applications of
perfluorocarbon droplets for ultrasound contrast enhancement was Echogen (Sonus
Pharmaceuticals), a perfluoropentane emulsion (Quay 1996). Clinical trials for Echogen
were abandoned in 2000 prior to FDA approval.
Once vaporized, ADV agents are readily detectable by an imaging system even at low
concentrations. In very small amounts, droplets when converted to bubbles through ADV
could act as point beacons for phase aberration corrections (Apfel 1998, Haworth et al.
2008). The unique advantages of ADV droplets in the hundred nanometer size range is that
they have the potential to extravasate from the vasculature and into the tissue, enabling ADV
based contrast imaging or therapy to extend beyond the vascular space, where traditional
microbubbles cannot access (Rapoport et al. 2007, Rapoport et al. 2009b, Sheeran et al.
2011.).
One of the most well studied applications of ADV is embolotherapy. This technique enables
the intentional creation of an occlusion in a specific tissue to limit blood flow. This has been
proposed to treat renal cell carcinoma, to reduce blood loss for hypervascular tumors, and to
treat hemhorrhage (Kripfgans et al. 2002, Zhang et al. 2010). Kripfgans et al. (2005)
demonstrated that a filtered emulsion of droplets which is intra-arterially injected can reduce
kidney perfusion by 70 %. This level of organ perfusion reduction has the ability to cause
ischemic necrosis for therapeutic applications, or can enhance the utility of radiofrequency
tissue ablation by minimizing thermally dissipative effects due to reduced flow (Kripfgans et
al. 2005). A second application of ADV agents is site-specific therapeutics, where the goal is
to deliver a potent agent only to the disease site while minimizing systemic effects. The
ADV-mediated delivery of a chemotherapeutic drug directly to the tumor has been shown to
mediate regression of ovarian and breast cancer (Rapoport et al. 2009a). ADV agents that
have the ability to carry a therapeutic payload to a desired vessel could be combined with
vessel occlusion upon activation to allow for an increase in residence time of the therapeutic
agent (Fabiilli et al. 2010).
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With spatial and temporal control over ADV agent activation, ADV agents can be used as a
nucleation site for high-intensity focused ultrasound (HIFU) tumor ablation. During HIFU,
the microdroplets can be activated to increase the therapeutic effect or decrease the
treatment time (Zhang and Porter 2010, Zhang et al. 2011).
Considerations of ADV agent size distribution
The size of ADV agents is an important factor in determining the vaporization threshold and
the biodistribution. The Antoine equation predicts a negative logarithmic relation between
droplet size and activation energy, where larger droplets require less energy to vaporize than
smaller droplets (Rapoport et al. 2009b). Most who have characterized ADV-based agents
have evaluated a polydisperse droplet population. While general trends in thresholds have
been observed, polydispersity in droplet sizes has led to a variability in the vaporization
threshold measured for studies that examine a bulk population of ADV droplets.
Additionally, the larger droplets vaporize at lower energies and the resulting bubbles can
influence the threshold energy for the smaller droplets (Lo et al. 2007), confounding in-vitro
characterization of vaporization thresholds. Since microbubbles combined with high
acoustic pressures can lead to unwanted bioeffects (Miller et al. 2008), it may be desirable to
perform ADV at the minimum acoustic pressure required. A polydisperse sample may
require a higher pressure to efficiently vaporize the entire population due to smaller droplets
requiring more energy.
For micron-sized ADV agents, one of the primary applications is vessel occlusion, where it
may be important to have a well characterized distribution of droplet sizes to target a
specific vascular diameter while not affecting other vessels (Kripfgans et al. 2005). For the
same reasons, a droplet designed for imaging applications that is too large could lodge in the
lungs or other organs after IV injection, leading to undesired vessel occlusion. All of these
limitations are motivating reasons for precise size control of ADV agents.
Previous studies to improve the size distribution characteristics of perfluorocarbon droplets
have involved microfluidic sorting (Huh et al. 2007) and filtering (Kripfgans et al. 2005).
The microfluidics platform is well known for the ability to create particles (Xu et al, 2005),
droplets (Tan et al. 2004, Xu et al. 2006, Teh et al. 2008), microbubbles (Hettiarachchi et al.
2007), and multi-layer/multi component compositions (Hettiarachchi et al. 2009, Wang et al.
2011) of uniform size. In this manuscript, we assess the feasibility for producing a




Liquid Perfluoropentane was purchased from FluoroMed, L.P. (Round Rock, Texas). Lipid
solutions were created using a 9:1 molar ratio of 1,2-distearoyl-sn-glycero-3-phosphocholine
(DSPC) (Avanti Polar Lipids, Alabaster, AL) and 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N[methoxy-(polyethylene glycol)-2000] (DSPE-PEG2000) (Avanti
Polar Lipids, Alabaster, AL) in a 110 mL solution of deionized water (DI), glycerol (Fisher
Scientific, Pittsburgh, PA), propylene glycol (Fisher Scientific, Pittsburgh, PA), and
pluronic F-68 (Sigma-Aldrich Corporation, St. Louis, MO).
50 mg of DPSC and 19.6 mg DSPE-PEG2000 were dissolved in chloroform. The
chloroform was then evaporated with N2, after which 50 mL of DI was added and the
resulting solution was sonicated for 20 minutes. After sonication, 47 mL DI, 2 mL glycerol,
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1 mL propylene glycol, and 10 mL pluronic F-68 were added. The solution was vortex
mixed for 1 minute and then sonicated for 10 minutes.
Microfluidic Device Fabrication
The process for developing the microfluidic wafer has been previously described by
Hettiarachchi el al. (2009). Briefly, the channels were created using Illustrator (Adobe, San
Jose, CA) and printed (20,000 dpi) by CAD/Art Services (Brandon, OR). In a clean room,
the wafer was first oxidized in oxygen plasma then spin-coated with a UV curable epoxy
(SU-8-25, MicroChem, Newton, MA). On exposing the wafer to UV light, the channel
patterns develop to use as a negative for device production.
With the wafer in a petri dish, Polydimethylsiloxane (PDMS) (Dow Corning, Midland, MI)
and a curing agent were poured over the wafer at a 10:1 ratio, respectively. This was then
placed under vacuum for 24 hours and then cured at 60°C overnight. After the PDMS was
cured, the individual microfluidic devices were removed from the wafer. The individual
microfluidic device and a clean microscope slide (2947-75×25, Corning, Corning, NY) were
placed in a plasma cleaner (Harrick Plasma, Ithaca, NY) and exposed to a plasma field under
a controlled pressure of 500 millitorr for 3 minutes. On completion of the plasma cleaning
process, the PDMS and glass slide were immediately joined, forming complete
microchannels. One minute after the bond was established, DI water was injected into the
channels to create a hydrophilic environment.
Microfluidic Experimental Apparatus
The microfluidic experimental apparatus was set up similar to that as described previously
by Kaya et al. (2010). Briefly, the microfluidic device was secured to a moving stand on an
inverted microscope (Olympus 1×71 microscope, Center Valley, PA), and viewed with a
50× NA = 0.5 objective. A high speed camera (Fastcam APX-RS, Photron, Inc., San Diego,
CA) was used to capture images and videos of the device output. Reagents were injected
from syringes into device channels through Tygon S-54-HL tubing (Saint-Gobain
Performance Plastics, Akron, OH). Calibrated syringe pumps (Harvard Apparatus,
Holliston, MA) were used to control rate of material flow in individual microchannels.
Sample Production
To produce uniform samples, the PFP flow rate was fixed at a constant value and the lipid
flow rate was increased until the smallest stable droplets were formed. The system was
allowed to stabilize for 5 minutes before collection, since pressure changes in the system
required a few minutes to equalize. This process was repeated across a range of different
flow rates, as described in Table 1. In order to determine the production rate for the
microfluidic device, high-speed video analysis of the droplet production was performed.
Time stamps enabled the determination of droplet production rate.
Acoustic Experimental Apparatus
The experimental setup to determine droplet vaporization thresholds was similar to that
previously described by (Sheeran et al. 2011). Briefly, a heated water bath maintained at
37°C was connected to an inverted microscope. Droplets were injected through a nearly
acoustically and optically transparent microcellulose capillary tube with an inner diameter of
200 μm (Spectrum Labs, Inc., Greensboro, NC). A 5 MHz piston transducer (IL0506HP,
Valpey Fisher Corp., Hopkinton, MA) was positioned in the water bath confocally with a
water immersion microscope objective (100×, NA=1.0). The output of the ultrasound
transducer was calibrated by inserting a needle-hydrophone (HNA-0400, Onda Corp.,
Sunnyvale, CA) into the experimental system at the exact location where the samples are
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positioned during activation studies (the focus of the microscope objective). Droplets were
exposed to single 10-cycle sinusoidal pulses, while the ultrasound pressure was increased
incrementally until droplet vaporization was observed. The procedure was repeated for at
least 20 droplets from each size distribution to verify droplet size and threshold.
Stability Analysis
Droplets were stored at 4°C in 3mL vials until sampling. For analysis, a 25 microliter
aliquot of droplets was placed on a glass slide, and images were captured with the Photron
Fastcam camera. Size measurements were performed in Image J (NIH, Bethesda, MD) by
comparison to a calibrated reticle (Edmund Industrial Optics, Barrington, NJ). A minimum
of 50 droplets were measured for each population.
Results
The dimensions of the microfluidic device, material composition, and flow rates all have the
ability to alter the composition of the resulting droplet. Due to the microfabrication process,
there are small variations from device to device (we measured a 13% deviation in orifice
widths across 10 devices). With this in mind, only one device was used for the duration of
production to ensure that the dimensions of the device were unchanged. The material
compositions also went unchanged to ensure that the droplets would experience a
standardized reaction to the US pressure.
Precision Size Control
The flow rates were varied over five sets of conditions for the duration of the experiment to
alter the droplet diameter. Results illustrated that by varying flow rates, the PFP population
diameters could be carefully selected. In general, as the lipid flow rate was increased,
droplet size decreased (Figure 1). As the PFP flow rate was increased, droplet size increased.
Table 1 lists the flow rates, mean droplet size, standard deviation, and polydispersity index
(Xu et al. 2006).
For the populations studied, the standard deviation was largest for the smallest droplets
(SD=0.4 for the 7.4 micron population) and smallest for the largest droplets (0.3 for the 20.4
micron population). All populations had a polydispersity index of 5.1 or less.
Production Rate
The 20-μL/min lipid and the 12.5 μL/min PFP flow rates, which resulted in 20.4 micron
droplets, had a production rate of 1.85×104 droplets produced per second (slowest
production sample); whereas the 60 μL/min lipid and 13.9 μL/min PFP flows, which
produced 7.4 micron droplets, had a production rate of 1.65×105 droplets per second (fastest
production sample). Table 2 lists the production rates for the 5 samples.
Acoustic Responses
The five samples were diluted and injected into a cellulose microcapillary tube where
droplets from each population were individually subjected to US. The US data showed that
there was a distinct vaporization threshold pressure for each diameter (Figure 2). The data
trend suggests a logarithmic relationship (P = -1.80ln(D) + 7.72, R2 = 0.97), as predicted by
the Antoine equation.
Long-tem stability
Populations maintained a fairly low polydispersity over a two week time period (Table 1),
and overall, the mean diameters of the populations drifted less than 4.6% (Figure 3). The
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16.2 and 10.3 μm mean diameter populations each maintained the same polydispersity, and
the 20.4, 12.6, and 7.4 μm mean diameter populations changed by a factor of 1.8, 1.3, and
1.9, respectively.
Discussion
The method described here demonstrates the potential of production of uniform-sized
droplets for acoustic droplet vaporization utilizing microfluidics. Data illustrates that this
technique enabled production of a population of droplets where each droplet responded
similarly to the same acoustic parameters due to uniform size. One advantage of utilizing
such uniform droplets would include the ability to use the lowest acoustic pressure possible
for vaporization (since all droplets would respond similarly), thereby achieving the highest
vaporization efficiency for the lowest acoustic pressure. Keeping the acoustic pressure as
low as required would conform to the “As Low As Reasonably Achievable (ALARA)
Principle” for clinical ultrasonics. Other potential advantages of uniform sized ADV agent
production, although not demonstrated here, would be the ability to tailor droplet sizes for
specific vessel occlusion, or to enable precision drug-loading for therapeutic-carrying ADV
agents.
Microfluidic techniques have previously demonstrated unique utility in the controlled
fabrication of droplets and microbubbles. The biggest limitation to this method to date is that
the production rate is substantially slower than other droplet and microbubble production
methods. Even for the fastest production method here, it would require nearly 3 hours to
achieve 1×109 droplets (a similar order of magnitude to the concentration of microbubble
contrast agents prepared by a mechanical agitation method). However, in the future
microfluidic techniques may be scaled up to achieve higher throughput, although the need to
maintain identical dimensions and flow rates to each orifice in order to preserve size
uniformity presents a challenge. It should also be noted that although the smallest droplets
described here were approximately 7 microns, which is likely too large for in-vivo
application, this size was limited only by our particular system, and is not a fundamental
limit of microfluidic droplet production. It is very reasonable to anticipate that by optimizing
the channel dimensions, component flow rates, and the lipid/perfluorocarbon ratios, droplets
much smaller than 7 microns can be prepared. Prior studies have illustrated microfluidic
production of liquid droplets as small as 100 nanometers (Tan and Lee, 2005).
Conclusion
A microfluidic device can produce monodisperse PFP/lipid droplets using flow focusing
technology. Monodisperse PFP/lipid droplets that were subjected to US pressure waves
showed a uniform ADV response. The relationship formed by droplet diameter and ADV
threshold agreed with the expected negative logarithmic response based on the size of the
droplets. Droplet populations produced with microfluidics were stable within the two week
time period studied.
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High speed video frames of microfluidic droplet production at diameters of (A) 20.4±0.3
μm, (B) 16.2±0.5 μm, (C) 12.6±0.5 μm, (D) 10.3±0.4 μm, and (E) 7.4± 0.4 μm,
corresponding to lipid and PFP flow rates of lipid 40 μL/min; PFP 12.5 μL/min, lipid 31
μL/min; PFP 15 μL/min, lipid 40 μL/min; PFP 15 μL/min, lipid 50 μL/min; PFP 15 μL/
min, and lipid 60 μL/min; PFP 13.9 μL/min, respectively.
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Average pressure of vaporization vs. average droplet diameter. Error bars indicate standard
deviations in pressure and diameter. The trendline is logarithmic.
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Microscopy images of droplets 1 week apart illustrating size stability. (A-E) 1 week after
production - populations of mean diameter of (A) 20.4±0.3 μm, (B) 16.2±0.5 μm, (C)
12.6±0.5 μm, (D) 10.3±0.4 μm, and (E) 7.4± 0.4 μm. (F-J) 2 weeks after production -
populations corresponding to (A-E), respectively, with mean diameters of (F) 20.4±0.5 μm,
(G) 15.5±0.5 μm, (H) 12.2±0.4 μm, (I) 10.8±0.4 μm, and (J) 7.5± 0.7 μm.
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